DTS-201

prodrug of doxorubicin for treatment of advanced or metastatic solid tumors; structure in first source

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Neoplasms (Cancer) 02/15/2008 - "The improved therapeutic index of DTS-201 compared with free doxorubicin was confirmed in three tumor xenograft models of prostate, breast, and lung cancer. " 02/15/2008 - "Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin." 02/15/2008 - "Neprilysin and thimet oligopeptidase expression, two enzymatic activators of DTS-201, was also characterized in human breast and prostate tumor biopsies. "
2.	Lung Neoplasms (Lung Cancer) 02/15/2008 - "The improved therapeutic index of DTS-201 compared with free doxorubicin was confirmed in three tumor xenograft models of prostate, breast, and lung cancer. "
3.	Cardiotoxicity 02/15/2008 - "The preclinical development program consisted of a detailed assessment of the general and cardiac toxicity profiles of DTS-201 in mice, rats, and dogs, together with mass balance and antitumoral efficacy studies in rodents. "
4.	Sarcoma (Soft Tissue Sarcoma) 11/01/2017 - "DTS-201 showed evidence of clinical activity with a confirmed partial response in a patient with soft-tissue sarcoma. "

1.	Doxorubicin (Adriamycin)
2.	Prodrugs
3.	Neprilysin (Neutral Endopeptidase)
4.	thimet oligopeptidase (endo-oligopeptidase)